Related Experiment Video
Updated: Aug 6, 2026
Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Immune checkpoint inhibitor (ICI) associated corneal allograft rejection
Philip Marjon1, Julio Echegoyen2, David J Schanzlin2
1California Cancer Associates for Research & Excellence (cCARE), San Marcos, California, USA.
This paper highlights a potential immune mediated effect of ICI's that is not well appreciated. The rejection of a corneal allograft with loss of vision should be taken into account in the treatment of these patients. RELEVANCE: With the rapid expansion of indications for ICI therapy and the prevalence of corneal graft transplantation, this information helps to identify patients that should be screened and followed by an ophthalmologist while on ICI therapy.
This paper highlights a potential immune mediated effect of ICI's that is not well appreciated. The rejection of a corneal allograft with loss of vision should be taken into account in the treatment of these patients. RELEVANCE: With the rapid expansion of indications for ICI therapy and the prevalence of corneal graft transplantation, this information helps to identify patients that should be screened and followed by an ophthalmologist while on ICI therapy.
